Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial

BACKGROUND: Anacetrapib is the only cholesteryl ester transfer protein inhibitor proven to reduce coronary heart disease (CHD). However, its effects on reverse cholesterol transport have not been fully elucidated. Macrophage cholesterol efflux (CEC), the initial step of reverse cholesterol transport...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Am Heart Assoc
Main Authors: Metzinger, Mark P., Saldanha, Suzanne, Gulati, Jaskeerat, Patel, Kershaw V., El‐Ghazali, Ayea, Deodhar, Sneha, Joshi, Parag H., Ayers, Colby, Rohatgi, Anand
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley and Sons Inc. 2020
Fag:
Original Research
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7955402/
https://ncbi.nlm.nih.gov/pubmed/33263263
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.120.018136
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker